Literature DB >> 7631125

Evaluation of suramin, ivermectin and CGP 20376 in a new macrofilaricidal drug screen, Onchocerca ochengi in African cattle.

A Renz1, A J Trees, D Achu-Kwi, G Edwards, G Wahl.   

Abstract

To aid the development of a macrofilaricidal agent for Onchocerca volvulus, the African bovine parasite, O. ochengi, was evaluated as a drug screen by testing three known filaricidal drugs. Groups of five Zebu cattle, naturally infected with more than 15 palpable O. ochengi nodules in the ventral skin, were treated with either suramin (10 mg/kg/day i.v. for 6 days), ivermectin (200 micrograms/kg, s.c.), CGP 20376 (20 mg/kg orally) or left untreated as controls and examined at intervals up to 137 days post-treatment (d.p.t.). After ivermectin treatment, microfilarial densities in the skin decreased within one week to virtually zero and remained at a very low level. A similar rapid and profound reduction was seen after CGP 20376 treatment, but by 137 d.p.t. microfilarial skin densities were approaching pre-treatment levels. With suramin, skin microfilarial densities fell to very low levels after 12 weeks but rose slightly by 137 d.p.t. Effects on the macrofilariae were assessed by sequential nodulectomies at -3 and 28, 84 and 137 d.p.t. By 137 d.p.t. embryogenesis was almost completely interrupted in the CGP 20376 and ivermectin treated animals, although not in the suramin treated group, but in all three groups the majority of remaining intrauterine microfilariae were pathologically altered. Degenerating intrauterine microfilariae accumulated in the ivermectin and in the CGP 20376, but not in the suramin treated worms. The motility of male and female worms was not reduced by any treatment except for female worms at 84 d.p.t. with CGP 20376. Viability of the worms as indicated by the MTT-formazan reduction assay was not reduced in any of the treatment groups.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7631125

Source DB:  PubMed          Journal:  Trop Med Parasitol        ISSN: 0177-2392


  14 in total

1.  Single worm genotyping demonstrates that Onchocerca ochengi females simultaneously produce progeny sired by different males.

Authors:  Julia C Hildebrandt; Albert Eisenbarth; Alfons Renz; Adrian Streit
Journal:  Parasitol Res       Date:  2012-06-17       Impact factor: 2.289

2.  Comparative analysis of macrophage migration inhibitory factors (MIFs) from the parasitic nematode Onchocerca volvulus and the free-living nematode Caenorhabditis elegans.

Authors:  Irene Ajonina-Ekoti; Marc Andre Kurosinski; Abuelhassan Elshazly Younis; Dieudonne Ndjonka; Manchang Kingsley Tanyi; Mbunkah Achukwi; Albert Eisenbarth; Caroline Ajonina; Kai Lüersen; Minka Breloer; Norbert W Brattig; Eva Liebau
Journal:  Parasitol Res       Date:  2013-07-03       Impact factor: 2.289

3.  Macrofilaricidal activity of tetracycline against the filarial nematode Onchocerca ochengi: elimination of Wolbachia precedes worm death and suggests a dependent relationship.

Authors:  N G Langworthy; A Renz; U Mackenstedt; K Henkle-Dührsen; M B de Bronsvoort; V N Tanya; M J Donnelly; A J Trees
Journal:  Proc Biol Sci       Date:  2000-06-07       Impact factor: 5.349

4.  Co-Administration of Adjuvanted Recombinant Ov-103 and Ov-RAL-2 Vaccines Confer Protection against Natural Challenge in A Bovine Onchocerca ochengi Infection Model of Human Onchocerciasis.

Authors:  Lisa Luu; Germanus S Bah; Ndode Herman Okah-Nnane; Catherine S Hartley; Alexandra F Glover; Tessa R Walsh; Lu-Yun Lian; Bin Zhan; Maria Elena Bottazzi; David Abraham; Nikolai Petrovsky; Nicolas Bayang; Bernard Tangwa; Rene Billingwe Ayiseh; Glory Enjong Mbah; David D Ekale; Vincent N Tanya; Sara Lustigman; Benjamin L Makepeace; John Graham-Brown
Journal:  Vaccines (Basel)       Date:  2022-05-27

5.  In a bovine model of onchocerciasis, protective immunity exists naturally, is absent in drug-cured hosts, and is induced by vaccination.

Authors:  Virginia L Tchakouté; Simon P Graham; Siv Aina Jensen; Benjamin L Makepeace; Charles K Nfon; Leo M Njongmeta; Sara Lustigman; Peter A Enyong; Vincent N Tanya; Albert E Bianco; Alexander J Trees
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

6.  Efficacy of three-week oxytetracycline or rifampin monotherapy compared with a combination regimen against the filarial nematode Onchocerca ochengi.

Authors:  Germanus S Bah; Emma L Ward; Abhishek Srivastava; Alexander J Trees; Vincent N Tanya; Benjamin L Makepeace
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

7.  Repeated high doses of avermectins cause prolonged sterilisation, but do not kill, Onchocerca ochengi adult worms in African cattle.

Authors:  Barend M deC Bronsvoort; Alfons Renz; Virginia Tchakouté; Vincent N Tanya; David Ekale; Alexander J Trees
Journal:  Filaria J       Date:  2005-08-08

8.  Design and descriptive epidemiology of the Infectious Diseases of East African Livestock (IDEAL) project, a longitudinal calf cohort study in western Kenya.

Authors:  Barend Mark de Clare Bronsvoort; Samuel Mwangi Thumbi; Elizabeth Jane Poole; Henry Kiara; Olga Tosas Auguet; Ian Graham Handel; Amy Jennings; Ilana Conradie; Mary Ndila Mbole-Kariuki; Philip G Toye; Olivier Hanotte; J A W Coetzer; Mark E J Woolhouse
Journal:  BMC Vet Res       Date:  2013-08-30       Impact factor: 2.741

9.  Immunisation with a multivalent, subunit vaccine reduces patent infection in a natural bovine model of onchocerciasis during intense field exposure.

Authors:  Benjamin L Makepeace; Siv Aina Jensen; Sandra J Laney; Charles K Nfon; Leo M Njongmeta; Vincent N Tanya; Steven A Williams; Albert E Bianco; Alexander J Trees
Journal:  PLoS Negl Trop Dis       Date:  2009-11-10

10.  UMF-078: A modified flubendazole with potent macrofilaricidal activity against Onchocerca ochengi in African cattle.

Authors:  Barend M Dec Bronsvoort; Benjamin L Makepeace; Alfons Renz; Vincent N Tanya; Lawrence Fleckenstein; David Ekale; Alexander J Trees
Journal:  Parasit Vectors       Date:  2008-06-20       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.